Rankings
▼
Calendar
ZVRA
Zevra Therapeutics, Inc.
$618M
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
+71.9% YoY
Gross Profit
$2M
100.0% margin
Operating Income
-$3M
-135.8% margin
Net Income
-$5M
-205.2% margin
EPS (Diluted)
$-1.07
QoQ Revenue Growth
+22.9%
Cash Flow
Operating Cash Flow
-$1M
Free Cash Flow
-$1M
Stock-Based Comp.
$457,000
Balance Sheet
Total Assets
$11M
Total Liabilities
$78M
Stockholders' Equity
-$66M
Cash & Equivalents
$4M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$1M
+71.9%
Gross Profit
$2M
-$569,000
+515.8%
Operating Income
-$3M
-$4M
+27.1%
Net Income
-$5M
-$6M
+19.6%
← FY 2020
All Quarters
Q1 2021 →
ZVRA Q4 2020 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena